New two-year data from Roche’s Phase IIIb/IV SALWEEN trial show that Vabysmo (faricimab) delivers durable vision gains and disease control in Asian patients with polypoidal choroidal vasculopathy (PCV), a severe subtype of neovascular age-related macular degeneration, while cutting treatment visits for the majority of patients.
Amgen and AstraZeneca announced that TEZSPIRE (tezepelumab-ekko) achieved statistically significant and clinically meaningful results across both co-primary endpoints and all key secondary endpoints in the Phase 3 CROSSING trial in eosinophilic esophagitis, with benefits sustained through week 52.
Roche’s next-generation KRAS G12C inhibitor, divarasib, has achieved statistical significance in a global head-to-head Phase III trial against sotorasib and adagrasib for advanced non-small cell lung cancer.
BridgeBio Pharma and Kyowa Kirin announced the publication of positive data from the global Phase 3 PROPEL 3 study of oral infigratinib for pediatric achondroplasia in The New England Journal of Medicine (NEJM), demonstrating unparalleled improvements in annualized height velocity and body proportionality.
The New England Journal of Medicine has retracted the pivotal 2021 clinical trial paper for Amgen’s rare-disease drug Tavneos (avacopan). The retraction follows an FDA investigation revealing undisclosed modifications to patient outcome data after the database was locked and unblinded.
Pfizer has announced topline Phase 3 results from its SigVie-002 study evaluating the investigational antibody-drug conjugate sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer.
Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in earlier-line relapsed or refractory multiple myeloma.
Johnson & Johnson has shared late-breaking results from its Phase 2 JASMINE trial highlighting that nipocalimab achieves a sustained reduction in systemic lupus erythematosus (SLE) disease activity through 52 weeks.
The Phase III SERENA-6 trial reveals that switching to AstraZeneca Camizestrant Breast Cancer Treatment yields a 55% reduction in disease progression risk for advanced HR-positive breast cancer patients with emergent ESR1 mutations.
Pfizer’s Phase 3 TALAPRO-3 trial reveals that combining Talzenna with Xtandi significantly improves radiographic progression-free survival by more than 50% in HRR gene-mutated mCSPC patients.
